Developer docs
API playgroundTry for free, no card

Search company profiles

Jubilant Pharmova

Full company profile

uuid000sdat

Namestring
Jubilant Pharmova
Legal namestring
Jubilant Pharmova Limited
Company typeenum
Public
Founded yearint
1978
Descriptiontext

Jubilant Pharmova Limited, founded in 1978 and headquartered in Noida, India, is a global pharmaceutical company listed on the NSE (JUBILANTPHARMOVA) and BSE (530019) and part of the Jubilant Bhartia Group. It operates through six business segments — Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO (Drug Discovery & API), Generics, and Proprietary Novel Drugs — serving global pharmaceutical customers with both contract services and finished-dose products. With FY26 revenue of ₹8,280 crore (approximately $1B), 10,000+ employees, and a growth rate of 14% YoY, it is a vertically integrated player spanning early-stage drug discovery, sterile injectable manufacturing, and commercial product supply.

The company's revenue model blends B2B contract development and manufacturing (CDMO Sterile Injectables and CRDMO) with B2C product sales (Generics, Allergy Immunotherapy, Radiopharma, Proprietary Novel Drugs). The CDMO Sterile Injectables franchise, anchored by the Spokane facility in the US, generated ₹1,755 crore in FY26 (up 38% YoY), with the Spokane site alone contributing ₹1,714 crore (up 48% YoY). Capital intensity is high: $132M has been invested in Spokane Line 3 as of October 2025, with $300M planned by FY28, and recent portfolio actions include the transfer of the API business to Jubilant Biosys in 2026.

Recent strategic activity includes a biologics/ADC partnership with Pierre Fabre (May 2026), tentative USFDA approval for Pantoprazole oral suspension (June 2026), a Spokane USFDA inspection yielding 8 non-sterility observations (June 2026), and the appointment of Daniel J O'Connor as CEO of the Proprietary Novel Drugs division. EBITDA margin narrowed 99 bps to 15.9% in FY26, primarily due to the Montreal facility shutdown, but normalised PAT still grew 7% YoY to ₹442 crore. The combined signals — strong CDMO growth, sustained capex, regulatory progress, and portfolio simplification — describe a company in execution-led expansion mode rather than a defensive turnaround.

Short descriptiontext

Jubilant Pharmova is a Noida-headquartered global pharmaceutical company operating across Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO, Generics, and Proprietary Novel Drugs. With FY26 revenue of ₹8,280 crore, it serves global pharma customers via B2B contract manufacturing and B2C specialty products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersNoida, India
HQ citystring
Noida
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices12 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical contract manufacturing, sterile injectable fill-finish, radiopharmaceutical products, generic drug manufacturing, drug discovery services
Industry5 codes
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAJ
Generic ANDA/Regulatory Affairs & Submissions
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model6 records
1CDMO Sterile Injectables
TypeManaged Services
Description

Contract manufacturing of sterile injectable pharmaceuticals for global pharma companies. Revenue of Rs 1,755 crore in FY26 with 38% growth, driven by incremental revenue from new Line 3 facility in Spokane, US. Growing demand from large US pharma companies seeking domestic manufacturing capacity amid new US tariffs.

tribuneindia.com
2Generics
TypeOne Time License
Description

Research and development, manufacture, sale and distribution of generic pharmaceuticals globally. Received tentative USFDA approval for Pantoprazole Sodium Delayed Release Oral Suspension, with final approval expected after December 2026 patent expiry.

tribuneindia.com
3Radiopharma
TypeManaged Services
Description

Development, manufacturing, commercialisation and distribution of radiopharmaceutical products.

jubilantpharmova.com
4Allergy Immunotherapy
TypeManaged Services
Description

Manufacturing and distribution of allergenic extracts and standard allergy vaccines. Offering over 200 different allergenic products.

jubilantpharmova.com
5Contract Research Development & Manufacturing Organisation (CRDMO)
TypeProfessional Services
Description

Drug discovery services and Active Pharmaceutical Ingredients (API) manufacturing. Completed transfer of API business to Jubilant Biosys Limited.

tribuneindia.com
6Proprietary Novel Drugs
TypeLicensing Royalties
Description

Clinical stage biopharmaceutical company developing precision oral medicines with enhanced therapeutic index.

jubilantpharmova.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Jubilant Radiopharma
Description

Development, manufacturing, commercialisation & distribution of radiopharmaceutical products

jubilantpharmova.com
+5 more records
Core offering1 text field

Jubilant Pharmova is an integrated pharmaceutical company that develops, manufactures and commercializes sterile injectables, radiopharmaceuticals, allergy immunotherapy products, generic drugs, active pharmaceutical ingredients (APIs) and proprietary novel drugs. It operates contract development and manufacturing (CDMO/CRDMO) services for global pharmaceutical companies across facilities in India, the United States and Canada, alongside proprietary product distribution in allergy immunotherapy, generics and radiopharma.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Revenue growth of 38% in CDMO Sterile Injectables segment to Rs 1,755 crore
+2 more records
Product overview1 text field

Jubilant Pharmova is an integrated global pharmaceuticals company organized into six distinct business segments: Radiopharma (radiopharmaceutical development and manufacturing), Allergy Immunotherapy (allergenic extracts and vaccines), CDMO Sterile Injectables (contract manufacturing of parenteral products), CRDMO (drug discovery and API manufacturing through Jubilant Biosys), Generics (vertically integrated generic pharmaceuticals), and Proprietary Novel Drugs (clinical-stage precision oral medicines). The company operates manufacturing facilities in India (Roorkee, Nanjangud, Noida, Greater Noida), USA (Spokane, Washington), and Canada (Montreal, Quebec), serving global pharmaceutical clients through contract development and manufacturing services.

Product and service6 records
1CDMO Sterile Injectables
CategoryContract Development and Manufacturing Organization (CDMO) — Sterile Injectables
Description

Contract manufacturing of sterile injectable (parenteral) products, ophthalmics, ointments, creams and liquids for global pharmaceutical innovator companies. Operated from Spokane, Washington and Montreal, Canada facilities through Jubilant HollisterStier LLC, with three sterile fill-and-finish lines and a fourth line planned (technology transfer revenues expected by Q4 FY27).

2Radiopharma
CategoryRadiopharmaceutical Products
Description

Development, manufacturing, commercialization and distribution of radiopharmaceutical products for medical diagnostics and therapy, operated through Jubilant DraxImage Limited with manufacturing in Montreal, Canada (Kirkland, Quebec).

3Allergy Immunotherapy
CategoryAllergy Immunotherapy Products
Description

Manufacturing and distribution of over 200 different allergenic extracts and standard allergy vaccines for allergy diagnosis and immunotherapy treatment, marketed under the HSS Allergy sub-brand.

4Contract Research Development & Manufacturing Organisation (CRDMO)
CategoryContract Research, Development and Manufacturing (CRDMO)
Description

Integrated drug discovery services and Active Pharmaceutical Ingredient (API) manufacturing operated through Jubilant Biosys Limited, providing end-to-end contract research, development and manufacturing for pharmaceutical partners globally.

5Generics
CategoryGeneric Pharmaceuticals
Description

Vertically integrated global generic pharmaceutical business engaged in research and development, manufacture, sale and distribution of generic drugs, operated through Jubilant Generics Limited and Jubilant Cadista Pharmaceuticals Inc. (US market), with manufacturing at the USFDA-approved Solid Dosage facility in Roorkee, Uttarakhand.

6Proprietary Novel Drugs
CategoryProprietary Pharmaceutical Pipeline (Clinical-stage)
Description

Clinical-stage biopharmaceutical pipeline of precision oral medicines with enhanced therapeutic index, developed and held through Jubilant Therapeutics.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-22
Description

Strategic partnership with Pierre Fabre of France for biologics and antibody-drug conjugates (ADC) development and manufacturing. This partnership strengthens Jubilant Pharmova's CDMO capabilities in the high-growth biologics and ADC segment, complementing its existing sterile injectables business and positioning the company to capture increasing outsourcing demand from global pharma companies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global CDMO leader across biologics, small molecules, and cell & gene therapies. Comparable to Jubilant Pharmova at the integrated CDMO/CRDMO level, particularly with the new Pierre Fabre-driven biologics/ADC capability.

TypeDirect peer
Description

Major US-headquartered CDMO with significant sterile injectable fill-finish capacity. Direct competitor to Jubilant HollisterStier in contract manufacturing of sterile injectables for global pharma.

3Recipharm
TypeDirect peer
Description

European-headquartered CDMO providing sterile fill-finish and injectable manufacturing services. Competes with Jubilant in contract manufacturing for global pharma customers.

TypeDirect peer
Description

India-based CDMO offering sterile injectables, API manufacturing, and drug discovery services. Direct competitor across multiple Jubilant business segments including CDMO and CRDMO.

5Syngene International
TypeDirect peer
Description

Indian CRO/CDMO providing drug discovery, development, and manufacturing services. Closely comparable to Jubilant Biosys's CRDMO offering and a key India-based CDMO peer.

TypeDirect peer
Description

Indian API and custom synthesis manufacturer. Comparable to Jubilant's API and contract manufacturing business with similar end markets among global generic and innovator pharma.

TypeDirect peer
Description

Radiopharmaceutical company focused on diagnostic imaging agents. Direct competitor to Jubilant DraxImage in radiopharma manufacturing and commercialization for diagnostic applications.

TypeBroad incumbent
Description

Large Indian generic pharmaceutical manufacturer with USFDA-approved facilities. Comparable to Jubilant Generics business serving the US generic drug market with similar regulatory profile.

TypeBroad incumbent
Description

Diversified Indian pharmaceutical company with generics, API, and proprietary products. Broad comparable across Jubilant's generics and proprietary novel drugs segments.

TypeDirect peer
Description

Global radiopharmaceutical manufacturer of diagnostic and therapeutic nuclear medicine products. Direct competitor to Jubilant's radiopharma business in the same specialty segment.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries16 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Jubilant Pharmova

Pharmaceutical Contract Development and Manufacturing (CDMO)jubilantpharmova.com

Jubilant Pharmova is a Noida-headquartered global pharmaceutical company operating across Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO, Generics, and Proprietary Novel Drugs. With FY26 revenue of ₹8,280 crore, it serves global pharma customers via B2B contract manufacturing and B2C specialty products.

What Jubilant Pharmova does

Jubilant Pharmova Limited, founded in 1978 and headquartered in Noida, India, is a global pharmaceutical company listed on the NSE (JUBILANTPHARMOVA) and BSE (530019) and part of the Jubilant Bhartia Group. It operates through six business segments — Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO (Drug Discovery & API), Generics, and Proprietary Novel Drugs — serving global pharmaceutical customers with both contract services and finished-dose products. With FY26 revenue of ₹8,280 crore (approximately $1B), 10,000+ employees, and a growth rate of 14% YoY, it is a vertically integrated player spanning early-stage drug discovery, sterile injectable manufacturing, and commercial product supply.

The company's revenue model blends B2B contract development and manufacturing (CDMO Sterile Injectables and CRDMO) with B2C product sales (Generics, Allergy Immunotherapy, Radiopharma, Proprietary Novel Drugs). The CDMO Sterile Injectables franchise, anchored by the Spokane facility in the US, generated ₹1,755 crore in FY26 (up 38% YoY), with the Spokane site alone contributing ₹1,714 crore (up 48% YoY). Capital intensity is high: $132M has been invested in Spokane Line 3 as of October 2025, with $300M planned by FY28, and recent portfolio actions include the transfer of the API business to Jubilant Biosys in 2026.

Recent strategic activity includes a biologics/ADC partnership with Pierre Fabre (May 2026), tentative USFDA approval for Pantoprazole oral suspension (June 2026), a Spokane USFDA inspection yielding 8 non-sterility observations (June 2026), and the appointment of Daniel J O'Connor as CEO of the Proprietary Novel Drugs division. EBITDA margin narrowed 99 bps to 15.9% in FY26, primarily due to the Montreal facility shutdown, but normalised PAT still grew 7% YoY to ₹442 crore. The combined signals — strong CDMO growth, sustained capex, regulatory progress, and portfolio simplification — describe a company in execution-led expansion mode rather than a defensive turnaround.

Jubilant Pharmova firmographics

Firmographics
Name
Jubilant Pharmova
Legal name
Jubilant Pharmova Limited
Website
https://jubilantpharmova.com
Company type
Public
Founded year
1978
Operating status
Operating
Headcount range
5,001–10,000 employees
Short description
Jubilant Pharmova is a Noida-headquartered global pharmaceutical company operating across Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO, Generics, and Proprietary Novel Drugs. With FY26 revenue of ₹8,280 crore, it serves global pharma customers via B2B contract manufacturing and B2C specialty products.
Ownership category
akta.pro rank

Jubilant Pharmova industry classification

Industry
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAJ
Generic ANDA/Regulatory Affairs & Submissions
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)

Keywords

  • Pharmaceutical contract manufacturing
  • Sterile injectable fill-finish
  • Radiopharmaceutical products
  • Generic drug manufacturing
  • Drug discovery services

Where Jubilant Pharmova is headquartered

Location

Headquarters

HQ city
Noida
HQ country
India
HQ region
Asia

Offices12 records

Markets served

Jubilant Pharmova business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. CDMO Sterile Injectables: Contract manufacturing of sterile injectable pharmaceuticals for global pharma companies. Revenue of Rs 1,755 crore in FY26 with 38% growth, driven by incremental revenue from new Line 3 facility in Spokane, US. Growing demand from large US pharma companies seeking domestic manufacturing capacity amid new US tariffs.
  2. Generics: Research and development, manufacture, sale and distribution of generic pharmaceuticals globally. Received tentative USFDA approval for Pantoprazole Sodium Delayed Release Oral Suspension, with final approval expected after December 2026 patent expiry.
  3. Radiopharma: Development, manufacturing, commercialisation and distribution of radiopharmaceutical products.
  4. Allergy Immunotherapy: Manufacturing and distribution of allergenic extracts and standard allergy vaccines. Offering over 200 different allergenic products.
  5. Contract Research Development & Manufacturing Organisation (CRDMO): Drug discovery services and Active Pharmaceutical Ingredients (API) manufacturing. Completed transfer of API business to Jubilant Biosys Limited.
  6. Proprietary Novel Drugs: Clinical stage biopharmaceutical company developing precision oral medicines with enhanced therapeutic index.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Jubilant Pharmova product offering

Product offering

Core offering

Jubilant Pharmova is an integrated pharmaceutical company that develops, manufactures and commercializes sterile injectables, radiopharmaceuticals, allergy immunotherapy products, generic drugs, active pharmaceutical ingredients (APIs) and proprietary novel drugs. It operates contract development and manufacturing (CDMO/CRDMO) services for global pharmaceutical companies across facilities in India, the United States and Canada, alongside proprietary product distribution in allergy immunotherapy, generics and radiopharma.

Product overview

Jubilant Pharmova is an integrated global pharmaceuticals company organized into six distinct business segments: Radiopharma (radiopharmaceutical development and manufacturing), Allergy Immunotherapy (allergenic extracts and vaccines), CDMO Sterile Injectables (contract manufacturing of parenteral products), CRDMO (drug discovery and API manufacturing through Jubilant Biosys), Generics (vertically integrated generic pharmaceuticals), and Proprietary Novel Drugs (clinical-stage precision oral medicines). The company operates manufacturing facilities in India (Roorkee, Nanjangud, Noida, Greater Noida), USA (Spokane, Washington), and Canada (Montreal, Quebec), serving global pharmaceutical clients through contract development and manufacturing services.

Differentiator

Problem solved

Functional benefit

Brands

  • Jubilant Radiopharma: Development, manufacturing, commercialisation & distribution of radiopharmaceutical products
  • Jubilant HollisterStier
  • Jubilant Biosys
  • Jubilant Generics
  • Jubilant Therapeutics
  • HSS Allergy

Products and services

  • CDMO Sterile Injectables Contract manufacturing of sterile injectable (parenteral) products, ophthalmics, ointments, creams and liquids for global pharmaceutical innovator companies. Operated from Spokane, Washington and Montreal, Canada facilities through Jubilant HollisterStier LLC, with three sterile fill-and-finish lines and a fourth line planned (technology transfer revenues expected by Q4 FY27).
  • Radiopharma Development, manufacturing, commercialization and distribution of radiopharmaceutical products for medical diagnostics and therapy, operated through Jubilant DraxImage Limited with manufacturing in Montreal, Canada (Kirkland, Quebec).
  • Allergy Immunotherapy Manufacturing and distribution of over 200 different allergenic extracts and standard allergy vaccines for allergy diagnosis and immunotherapy treatment, marketed under the HSS Allergy sub-brand.
  • Contract Research Development & Manufacturing Organisation (CRDMO) Integrated drug discovery services and Active Pharmaceutical Ingredient (API) manufacturing operated through Jubilant Biosys Limited, providing end-to-end contract research, development and manufacturing for pharmaceutical partners globally.
  • Generics Vertically integrated global generic pharmaceutical business engaged in research and development, manufacture, sale and distribution of generic drugs, operated through Jubilant Generics Limited and Jubilant Cadista Pharmaceuticals Inc. (US market), with manufacturing at the USFDA-approved Solid Dosage facility in Roorkee, Uttarakhand.
  • Proprietary Novel Drugs Clinical-stage biopharmaceutical pipeline of precision oral medicines with enhanced therapeutic index, developed and held through Jubilant Therapeutics.

Quantifiable outcome

  • Revenue growth of 38% in CDMO Sterile Injectables segment to Rs 1,755 crore
  • +2 more outcomes

Companies that use Jubilant Pharmova

Customer profile

Segments4 records

Ideal customer profiles3 records

Jubilant Pharmova technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Jubilant Pharmova partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Pierre FabrecoreStrategic or Co-development Partner · 22 May 2026Strategic partnership with Pierre Fabre of France for biologics and antibody-drug conjugates (ADC) development and manufacturing. This partnership strengthens Jubilant Pharmova's CDMO capabilities in the high-growth biologics and ADC segment, complementing its existing sterile injectables business and positioning the company to capture increasing outsourcing demand from global pharma companies.

Scale indicators15 records

Recent moves7 records

Expansion highlights5 records

Jubilant Pharmova competitors and assessment

Company assessment

Broad incumbents

  • Lonza Group: Global CDMO leader across biologics, small molecules, and cell & gene therapies. Comparable to Jubilant Pharmova at the integrated CDMO/CRDMO level, particularly with the new Pierre Fabre-driven biologics/ADC capability.
  • Aurobindo Pharma: Large Indian generic pharmaceutical manufacturer with USFDA-approved facilities. Comparable to Jubilant Generics business serving the US generic drug market with similar regulatory profile.
  • Dr. Reddy's Laboratories: Diversified Indian pharmaceutical company with generics, API, and proprietary products. Broad comparable across Jubilant's generics and proprietary novel drugs segments.

Direct peers

  • Catalent: Major US-headquartered CDMO with significant sterile injectable fill-finish capacity. Direct competitor to Jubilant HollisterStier in contract manufacturing of sterile injectables for global pharma.
  • Recipharm: European-headquartered CDMO providing sterile fill-finish and injectable manufacturing services. Competes with Jubilant in contract manufacturing for global pharma customers.
  • Piramal Pharma Solutions: India-based CDMO offering sterile injectables, API manufacturing, and drug discovery services. Direct competitor across multiple Jubilant business segments including CDMO and CRDMO.
  • Syngene International: Indian CRO/CDMO providing drug discovery, development, and manufacturing services. Closely comparable to Jubilant Biosys's CRDMO offering and a key India-based CDMO peer.
  • Divi's Laboratories: Indian API and custom synthesis manufacturer. Comparable to Jubilant's API and contract manufacturing business with similar end markets among global generic and innovator pharma.
  • Lantheus Holdings: Radiopharmaceutical company focused on diagnostic imaging agents. Direct competitor to Jubilant DraxImage in radiopharma manufacturing and commercialization for diagnostic applications.
  • Curium Pharma: Global radiopharmaceutical manufacturer of diagnostic and therapeutic nuclear medicine products. Direct competitor to Jubilant's radiopharma business in the same specialty segment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Jubilant Pharmova social profiles

Digital presence

Jubilant Pharmova financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Jubilant Pharmova leadership team

Management profile

Number of profiles

Profiles12 records

Jubilant Pharmova subsidiaries and ownership

Company hierarchy

Subsidiaries16 records

Jubilant Pharmova funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Jubilant Pharmova M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jubilant Pharmova

What does Jubilant Pharmova do?

Jubilant Pharmova is an integrated pharmaceutical company that develops, manufactures and commercializes sterile injectables, radiopharmaceuticals, allergy immunotherapy products, generic drugs, active pharmaceutical ingredients (APIs) and proprietary novel drugs. It operates contract development and manufacturing (CDMO/CRDMO) services for global pharmaceutical companies across facilities in India, the United States and Canada, alongside proprietary product distribution in allergy immunotherapy, generics and radiopharma.

Is Jubilant Pharmova a public or private company?

Jubilant Pharmova is a public company. It is classified as public and is currently operating.

When was Jubilant Pharmova founded?

Jubilant Pharmova was founded in 1978. It employs 5,001 to 10,000 people.

Where is Jubilant Pharmova based?

Jubilant Pharmova is headquartered in Noida, India, in the Asia region.

How does Jubilant Pharmova make money?

Six revenue lines are on record. CDMO Sterile Injectables are the primary driver. The others are generics, radiopharma, allergy Immunotherapy, contract Research Development & Manufacturing Organisation (CRDMO) and proprietary Novel Drugs.

Who are Jubilant Pharmova's main competitors?

Broad incumbents on record are Lonza Group, Aurobindo Pharma and Dr. Reddy's Laboratories. Direct peers are Catalent, Recipharm, Piramal Pharma Solutions, Syngene International, Divi's Laboratories, Lantheus Holdings and Curium Pharma.

Does Jubilant Pharmova have an API?

No public API is recorded for Jubilant Pharmova.

What industry is Jubilant Pharmova in?

Jubilant Pharmova's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAIAGAF, Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comEarnings call transcript: Jubilant Pharmova tops revenue in Q2 2026, shares riseJubilant Pharmova reported Q2 FY2027 revenue of INR 2,370 crore, up 21% year-on-year, but EPS of 4.6 missed the 5.8 forecast. Montreal facility losses exceeded INR 80 crore, and management guided H2 average EBITDA margins to the mid-teens. The company expects margin recovery in H2 and reiterated its zero net debt target by FY2030.TradingViewJubilant Pharmova Q2 2027 Earnings Call Is LiveJubilant Pharmova's Q2 2027 earnings call is live, with executives discussing financial results and answering analyst questions. Management commentary on demand, margins, or capital spending may move markets.ET NOWStocks to watch today, November 16: Tata Motors PV, Eicher Motors, Pricol, Jubilant Pharmova, Yes Bank and othersShares of Tata Motors PV, Eicher Motors, Pricol, and others are expected to trade on November 16 after Q2 FY27 earnings. Tata Motors PV reported a net loss of Rs 5,531 crore, while Eicher Motors posted best quarterly sales. Yes Bank filed a review petition challenging a Supreme Court judgment on its AT1 write-down.CNBCTV18Earnings Central: From Tata Motors, Eicher and Manipal Health to Jubilant Pharmova, the hits and misses - CNBC TV18Tata Motors reported a net loss of ₹5,531 crore in Q2 FY27, while Manipal Health and Jubilant Pharmova saw profit drops. Godrej Industries more than doubled net profit to ₹559.6 crore, and Inox Green Energy surged 54.8% to ₹43 crore. Sector headwinds may threaten upcoming margin recovery.CNBCTV18Jubilant Pharmova Q2 Results: Net profit falls as sterile injectables, radiopharma earnings decline - CNBC TV18Jubilant Pharmova reported a 74.1% year-on-year drop in net profit to ₹31.2 crore for Q2 FY27, despite revenue rising 20.5% to ₹2,370 crore. EBITDA margin contracted to 10.2% from 17.4%, driven by losses in sterile injectables and radiopharma. Management expects competitive intensity to rise in large-pharma customers.ScanXJubilant Pharmova to present JBI-802 Phase 1 clinical data at ASH meetingJubilant Therapeutics will present Phase 1/2 data for JBI-802 at the ASH Annual Meeting on December 14, 2026. All eight patients at 15 mg achieved >50% platelet reduction or normalization by Week 3, with median response time of 15 days. Platelet normalization was maintained through 46 weeks in patients with over 12 weeks of follow-up.The Times of IndiaJubilant Pharmova plans to raise ₹800 crore via maiden bond issueJubilant Pharmova is raising ₹800 crore via its maiden bond issue, with a base of ₹400 crore and an equal greenshoe option. The bonds carry a three-year tenure at about 8.50% and will fund capital expenditure and expansion. Book-building is expected later this week.TradingViewJubilant Pharmova to Raise 800 cr via Maiden Bond IssueJubilant Pharmova is raising 800 crore via its maiden bond issue, with a base of 400 crore and an equal greenshoe option. The bonds carry a three-year tenure and are priced around 8.50%, likely subscribed by mutual funds and asset managers. Book-building and final bidding are expected later this week.The Times of IndiaJubilant Pharmova plans to raise Rs 800 crore via maiden bond issueJubilant Pharmova plans to raise Rs 800 crore via its first local bond issue, with Rs 400 crore as base and an equal greenshoe option. The bonds carry a three-year tenure at an indicative 8.50% rate, and proceeds will fund capital expenditure and expansion. Book-building and bidding are expected later this week.TradingViewJubilant Pharmova eyes $150 million through rupee debt sale, bankers sayJubilant Pharmova plans to raise about ₹1,400 crore ($150 million) through a three-year rupee bond offering, primarily for capital expenditure. The bonds carry an AA+ rating from India Ratings, and the company could tap the market before the end of next month.